CTT2274 is a prodrug of MMAE. It consists of a prostate-specific membrane antigen (PSMA) binding scaffold, a biphenyl motif, a pH-sensitive phosphoramidate linker, and an MMAE payload. CTT2274 selectively targets and binds to PSMA to deliver MMAE and has the capability to inhibit prostate cancer.
Molecular Weight:
2417.58
Formula:
C119H159N17O33P2
Target:
PSMA
T205193
* VAT and and shipping costs not included. Errors and price changes excepted
